Timothy D Wiltshire
Overview
Explore the profile of Timothy D Wiltshire including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
189
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Krull A, DiGuardo M, Deeds M, Skaer C, Soiney K, Wadewitz M, et al.
Cytotherapy
. 2025 Feb;
PMID: 39969436
The rapidly evolving field of cell and gene therapy (CGT) demands a new generation of leaders capable of managing complex manufacturing processes while navigating stringent regulatory environments. To address this...
2.
Cable J, Saphire E, Hayday A, Wiltshire T, Mousa J, Humphreys D, et al.
Ann N Y Acad Sci
. 2022 Nov;
1519(1):153-166.
PMID: 36382536
Therapeutic antibodies have broad indications across diverse disease states, such as oncology, autoimmune diseases, and infectious diseases. New research continues to identify antibodies with therapeutic potential as well as methods...
3.
Li M, Beck E, Laeyendecker O, Eby Y, Tobian A, Caturegli P, et al.
Blood Adv
. 2022 Apr;
6(12):3678-3683.
PMID: 35443020
The ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants severely limits available effective monoclonal antibody therapies. Effective drugs are also supply limited. COVID-19 convalescent plasma (CCP) qualified...
4.
Li M, Beck E, Laeyendecker O, Eby Y, Tobian A, Caturegli P, et al.
medRxiv
. 2022 Mar;
PMID: 35262085
Key Points: All of the post-delta COVID-19/post vaccination convalescent plasma effectively neutralizes the omicron and delta variants.High-titer CCP and hyperimmunoglobulin neutralizes SARS-CoV-2 variants despite no previous donor exposure to the...
5.
Wiltshire T, Deeds M, Radel D, Bornschlegl A, Schmidt C, Thebiay J, et al.
Cytotherapy
. 2022 Jan;
24(1):19-26.
PMID: 34980364
Background: The rise of investigative and commercially available cell therapy products adds a new dynamic to academic medical centers; that is, the management of patient-specific cell products. The scope of...
6.
Wiltshire T, Milosevic D, Jacob E, Grebe S, Dietz A
Cytotherapy
. 2021 Mar;
23(5):452-458.
PMID: 33715950
Background Aims: Viral vectors are commonly used to introduce chimeric antigen receptor (CAR) constructs into cell therapy products for the treatment of human disease. They are efficient at gene delivery...
7.
Murphy S, Hart S, Halling G, Johnson S, Smadbeck J, Drucker T, et al.
Cancer Res
. 2015 Dec;
76(3):749-61.
PMID: 26676757
Many somatic mutations have been detected in pancreatic ductal adenocarcinoma (PDAC), leading to the identification of some key drivers of disease progression, but the involvement of large genomic rearrangements has...
8.
Singh N, Basnet H, Wiltshire T, Mohammad D, Thompson J, Heroux A, et al.
Proc Natl Acad Sci U S A
. 2012 Aug;
109(36):14381-6.
PMID: 22908299
Tyr142, the C-terminal amino acid of histone variant H2A.X is phosphorylated by WSTF (Williams-Beuren syndrome transcription factor), a component of the WICH complex (WSTF-ISWI chromatin-remodeling complex), under basal conditions in...
9.
Singh N, Wiltshire T, Thompson J, Mer G, Couch F
J Biol Chem
. 2011 Dec;
287(4):2854-62.
PMID: 22139841
Microcephalin (MCPH1), the first gene identified as causative for primary recessive autosomal microcephaly, is aberrantly expressed in autism-like disorders and human malignancy of breast and ovarian origin. MCPH1, the encoded...
10.
Wiltshire T, Lovejoy C, Wang T, Xia F, OConnor M, Cortez D
J Biol Chem
. 2010 Mar;
285(19):14565-71.
PMID: 20233726
DNA damage repair and checkpoint responses prevent genome instability and provide a barrier to the development of cancer. Inherited mutations in DNA damage response (DDR) genes such as those that...